-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Yesterday, BLOOD released the results of a phase II study, showing that in myeloma patients who have received a median of 4 treatment routes, adding dexamethasone to ISAtuximab can increase the ORR from 23.
Yesterday, BLOOD released the results of a phase II study, showing that in myeloma patients who have received a median of 4 treatment routes, adding dexamethasone to ISAtuximab can increase the ORR from 23.
This phase II study evaluated the efficacy and safety of ISAtuximab monotherapy or combined with dexamethasone in the treatment of relapsed/refractory multiple myeloma (RRMM).
This phase II study evaluated the efficacy and safety of ISAtuximab monotherapy or combined with dexamethasone in the treatment of relapsed/refractory multiple myeloma (RRMM).
A total of 164 patients were enrolled in the study, and the median number of their previous treatments was 4 treatment routes (2-10).
The study does not have the right to compare treatment groups.
The PFS and OS of the ISA group were 4.
The PFS and OS of the ISA group were 4.
The median duration of OS follow-up for ISA and ISA-dex were 12.
OS was evaluated based on 50 deaths in the ISA arm (45.
Among patients with a post-baseline paraprotein assessment ≥1, 37.
Among patients with a post-baseline paraprotein assessment ≥1, 37.
More than 91% of patients had a treatment emergency AE (TEAE) of grade ≥1.
More than 91% of patients had a treatment emergency AE (TEAE) of grade ≥1.
All in all, adding dexamethasone to ISAtuximab can increase the remission rate and improve the survival outcome without adversely affecting safety.
In this study, the ORR using ISA-dex was 44%, compared with that observed with pomalidomide + dexamethasone (33% ORR), 28 carfilzomib + dexamethasone (55%), 29 selinexor and dexamethasone (22%) Compared with clinical response rate, it has advantages.
Dexamethasone improves the efficacy of ISAtuximab in the treatment of RRMM, and has no adverse effect on safety.
This study provides a rationale for the effective combination therapy of dexamethasone and ISA.
This study provides a rationale for the effective combination therapy of dexamethasone and ISA.
Dexamethasone improves the efficacy of ISAtuximab in the treatment of RRMM, and has no adverse effect on safety.
Original document:
Original document:Meletios Dimopoulos, Sara Bringhen, Pekka Anttila, et al.
ISAtuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
Blood (2021) 137 (9): 1154–1165.
ISAtuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma.
Blood (2021) 137 (9): 1154–1165.
org/10.
1182/blood.
2020008209">https://doi.
org/10.
1182/blood.
2020008209
1182/blood.
2020008209">https://doi.
org/10.
1182/blood.
2020008209 org/10.
1182/blood.
2020008209"> https://doi.
org/10.
1182/blood.
2020008209 Leave a message here
